Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Since the first US Food and Drug Administration approval of a Janus kinase (JAK) inhibitor in 2011, the number of these medications available — and their treatment indications — have continued to grow ...
• BTK inhibitors work by targeting and blocking the BTK enzyme, which is crucial for the survival and growth of cancerous B-cells in mantle cell lymphoma (MCL). This cuts off the cancer cell’s support ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (A ...
Patients with COPD and heart failure treated with SGLT-2 inhibitors experienced higher rates of volume depletion and adverse renal events. Chronic obstructive pulmonary disease (COPD) reduces the ...
Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and ...
Angiotensin converting enzyme (ACE) inhibitors, a type of blood pressure medication, are usually well tolerated, but one of their rare side effects is angioedema. Angiotensin converting enzyme (ACE) ...
The last time I wrote about Recursion Pharmaceuticals (RXRX) it was with respect to a Seeking Alpha article entitled "Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245". In ...
Patients with T2D who received GLP-1RAs or SGLT2 inhibitors were not associated with an increased risk for ARDs compared with DPP4 inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results